Evidence map›Paper›PMID 38757972›Full record

ArticleJournal of virology2024

Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.

Ieva Bagdonaite, Samir Abdurahman, Mattia Mirandola, Denis Pasqual, Martin Frank, Yoshiki Narimatsu, Hiren J Joshi, Sergey Y Vakhrushev, Cristiano Salata, Ali Mirazimi and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Multiplexed Detection of Autoantibodies to Glycopeptides Using Microarray.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ieva BagdonaiteDepartment of Cellular and Molecular Medicine, Copenhagen Center for Glycomics, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-9383-8448
Samir AbdurahmanPublic Health Agency of Sweden, Solna, Sweden.
Mattia MirandolaDepartment of Molecular Medicine, University of Padua, Padua, Italy.
Denis PasqualDepartment of Molecular Medicine, University of Padua, Padua, Italy.
Martin FrankBiognos AB, Gothenburg, Sweden.
Yoshiki NarimatsuDepartment of Cellular and Molecular Medicine, Copenhagen Center for Glycomics, University of Copenhagen, Copenhagen, Denmark.
Hiren J JoshiDepartment of Cellular and Molecular Medicine, Copenhagen Center for Glycomics, University of Copenhagen, Copenhagen, Denmark.
Sergey Y VakhrushevDepartment of Cellular and Molecular Medicine, Copenhagen Center for Glycomics, University of Copenhagen, Copenhagen, Denmark.
Cristiano SalataDepartment of Molecular Medicine, University of Padua, Padua, Italy.ORCID 0000-0002-5136-7406
Ali MirazimiPublic Health Agency of Sweden, Solna, Sweden.ORCID 0000-0003-2371-6055
Hans H WandallDepartment of Cellular and Molecular Medicine, Copenhagen Center for Glycomics, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0240-9232

Funding

European Commission (EC) GlycoSkin H2020-ERCInnovative Medicines Initiative 2 Joint Undertaking 823666Lundbeck Foundation (Lundbeckfonden) R219-2016-545Lundbeck Foundation (Lundbeckfonden) R313-2019-869Neye FoundationUniversità degli Studi di Padova (UNIPD) DOR 2021
6 · The paper itself

Abstract

Ebola virus glycoprotein (EBOV GP) is one of the most heavily O-glycosylated viral glycoproteins, yet we still lack a fundamental understanding of the structure of its large O-glycosylated mucin-like domain and to what degree the host O-glycosylation capacity influences EBOV replication. Using tandem mass spectrometry, we identified 47 O-glycosites on EBOV GP and found similar glycosylation signatures on virus-like particle- and cell lysate-derived GP. Furthermore, we performed quantitative differential O-glycoproteomics on proteins produced in wild-type HEK293 cells and cell lines ablated for the three key initiators of O-linked glycosylation, GalNAc-T1, -T2, and -T3. The data show that 12 out of the 47 O-glycosylated sites were regulated, predominantly by GalNAc-T1. Using the glycoengineered cell lines for authentic EBOV propagation, we demonstrate the importance of O-linked glycan initiation and elongation for the production of viral particles and the titers of progeny virus. The mapped O-glycan positions and structures allowed to generate molecular dynamics simulations probing the largely unknown spatial arrangements of the mucin-like domain. The data highlight targeting

Indexed as

EbolavirusPolysaccharidesVirus ReplicationGlycoproteinsGlycosylationHEK293 CellsHemorrhagic Fever, EbolaHumansN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseViral Envelope Proteinsenvelope glycoprotein, Ebola virusGlycoproteinsN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferasePolysaccharidesViral Envelope ProteinsEbola virusGalNAc-Tglycosyltransferasemass spectrometrymucin-like domainO-glycosylationpost-translational modificationtandem mass tagviral glycoprotein

Identifiers

PMID38757972
PMCPMC11237518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.